• Binimetinib is effective in preclinical models of neuroblastoma tumors with low NF1 expression.• Binimetinib and CDK4/6 inhibitors are synergistic in preclinical models of neuroblastoma. This evidence concerns the gene CDK4 and neuroblastoma.